Gliomas are a primary types of intracranial malignancies and are characterized by a poor
prognosis due to aggressive recurrence profiles. Temozolomide (TMZ) is an auxiliary …

Glioblastoma, also known as glioblastoma multiforme, is the most aggressive brain tumor in
adults. Despite the huge advance in developing novel therapeutic strategies for patients with …

Glioma originates in the central nervous system and is classified based on both histological
features and molecular genetic characteristics. Long non-coding RNAs (lncRNAs) are …

Temozolomide (TMZ) and radiation therapy combination for glioblastoma (GB) patients has
been considered as the most effective therapy after surgical procedure. However, the overall …

Brain tumors, which are highly malignant, pose a significant threat to health and often result
in substantial rates of mortality and morbidity worldwide. The brain cancer therapy has been …

Simple Summary Glioblastoma (GBM) is the most aggressive brain tumor and most resistant
to therapy. The identification of novel predictive biomarkers or targets to counteract …

As the most common primary tumour of the central nervous system, gliomas have a high
recurrence rate after surgical resection and are resistant to chemotherapy, particularly high …

Glioblastoma (GBM) is the most common and aggressive primary adult brain tumor, with an
estimated annual incidence of 17 000 new cases in the United States. Current treatments for …

Temozolomide (TMZ) is an alkylating chemotherapeutic agent widely used in anti-glioma
treatment. However, acquired TMZ resistance represents a major clinical challenge that …

Resistance to temolozomide (TMZ), the standard chemotherapy agent for treating
glioblastomas (GBM), is a major clinical problem for patients with GBM. Recently, long …